Navigation Links
WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
Date:9/4/2007

Earnings Conference Call to be Held on September 6, 2007 at 8:00 am

(Eastern) / 5:00 am (Pacific) / 8:00 pm (Beijing/Hong Kong)

SHANGHAI, China, Sept. 4 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) ("WuXi PharmaTech" or ''the Company''), the leading China- based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release unaudited financial results for the second quarter ended June 30, 2007 before the US market opens on Thursday, September 6, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The earnings release will be available on the investor relations page of its website at http://www.wuxipharmatech.com .

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (Eastern) / 5:00 am (Pacific) / 8:00 pm (Beijing/Hong Kong) on Thursday, September 6, 2007 to discuss its 2007 second quarter financial results and recent business activity. The conference call may be accessed by calling (US) +1 718 354 1157 / (UK) +44 (0)20 7138 0815 / (HK) +852 3002 1616. A telephone replay will be available shortly after the call until October 5, 2007 at (US) +1 718 354 1112/ (UK) +44 (0)20 7806 1970 / (HK) +852 3002 1607, Passcode: 1468987.

A live webcast of the conference call and replay will be available on the Investor Relations page of WuXi PharmaTech's website at http://www.wuxipharmatech.com .

About WuXi PharmaTech

Founded in 2000, Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research- driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, pharmaceutical development and process development services, and manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use. In 2006, WuXi PharmaTech provided services to 70 pharmaceutical and biotechnology customers, including nine of the top ten pharmaceutical companies in the world, as measured by 2006 total revenues. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Investor Contact:

Dr. Hai Mi

Vice President, Corporate Communications

WuXi PharmaTech Co., Ltd

Tel: +86-21-5046-3726

Email: ir@pharmatechs.com

Investor Relations (US):

Mahmoud Siddig

Director

Taylor Rafferty

Tel: +1-212-889-4350

Email: Pharmatechs@taylor-rafferty.com

Investor Relations (HK):

Ruby Yim

Managing Director

Taylor Rafferty

Tel: +852-3196-3712

Email: Pharmatechs@taylor-rafferty.com

Media Contact:

John Dooley

Taylor Rafferty

Tel: +1-212-889-4350

Email: Pharmatechs@taylor-rafferty.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Use of the PROTEAN Plus Dodeca Cell for Second-Dimension SDS-PAGE, Rev A
2. In Vitro Measurement of the Second Messenger cAMP: RIA vs. FlashPlate
3. CIOs looking to hire more IT workers in second quarter
4. DNASTAR catches second wave of sequencing
5. 9 tips for making 90 seconds count in an investment pitch
6. City of Hope adds second TomoTherapy system
7. UW-Madison hybrid-vehicle team places second nationally
8. Just one nanosecond: Clocking events at the nanoscale
9. MATCs new computer security program gears up for second semester
10. Weather Central launches second satellite
11. nPoint Secures Second Round of Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... Maryland (PRWEB) , ... April 26, 2017 , ... ... will be demonstrating its new Bioflash MailGuardtm mail security screening solution at the ... The Bioflash MailGuard system provides a fast, highly accurate, easy to use ...
(Date:4/26/2017)... , April 26, 2017  Genisphere LLC, ... platform, has signed a collaborative and sponsored research ... Silvia Muro . The overall goal of ... pharmacodynamics of various 3DNA designs and formulations after ... targeting diseases of the vasculature as well as ...
(Date:4/25/2017)... Diego, CA (PRWEB) , ... April 25, 2017 ... ... division of L3 Healthcare, is pleased to announce the company is now a ... management. The iMedNet software certification enables the company’s clinical research team to ...
(Date:4/25/2017)... ... April 25, 2017 , ... Covalent Metrology ... Analytical Services unit provides high-quality data to clients, both faster and cheaper ... receipt. There are no price premiums, and customers are welcome to participate in ...
Breaking Biology Technology:
(Date:3/23/2017)... , Mar. 23, 2017 Research and ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 8.8% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
(Date:3/22/2017)... , March 21, 2017 Optimove ... used by retailers such as 1-800-Flowers and AdoreMe, ... — Product Recommendations and Replenishment. Using Optimove,s machine learning ... personalized product and replenishment recommendations to their customers ... on predictions of customer intent drawn from a ...
(Date:3/20/2017)... Germany , March 20, 2017 At this ... Hamburg -based biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG ... is this year,s CeBIT partner country. At the largest German ... biometrics in use: fingerprint, face and iris recognition as well as DERMALOG´s ... ...
Breaking Biology News(10 mins):